Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3

5 days ago 8

Soumya Eswaran

Tue, November 25, 2025 astatine 6:32 AM CST 3 min read

Carillon Tower Advisers, an concern absorption company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. In the 3rd quarter, the equity markets continued their rally, fueled by enthusiasm for AI, constricted grounds of inflationary effects from tariffs, and expectations for further involvement complaint cuts from the U.S. Federal Reserve. Mid-cap stocks besides maintained their affirmative gains during the quarter. The Russell Midcap Growth Index (up 2.78%) underperformed the Russell Midcap® Value Index (up 6.16%) successful the quarter. The missive further shared the firm's elaborate views connected Cyclicals, Healthcare, Information Technology, Financials, and Consumer sectors. In addition, you tin cheque the fund’s apical 5 holdings to find its champion picks for 2025.

In its third-quarter 2025 capitalist letter, Carillon Eagle Mid Cap Growth Fund highlighted stocks specified arsenic Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) discovers and commercializes therapeutics based connected ribonucleic acerb interference. The one-month instrumentality of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was -8.76%, and its shares gained 71.40% of their worth implicit the past 52 weeks. On November 24, 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) banal closed astatine $434.23 per share, with a marketplace capitalization of $57.368 billion.

Carillon Eagle Mid Cap Growth Fund stated the pursuing regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) successful its 3rd 4th 2025 capitalist letter:

"Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is simply a starring institution focused connected processing gene-silencing technologies to code important unmet aesculapian needs. The motorboat of vutrisiran for transthyretin (TTR) amyloidosis exceeded expectations, with second-quarter income coming successful good supra statement expectations. The institution besides substantially raised its TTR income guidance, which drove the banal higher."

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 58 hedge money portfolios held Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) astatine the extremity of the 2nd quarter, which was 59 successful the erstwhile quarter. In the 3rd 4th of 2025, the product revenue of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) grew 103% year-over-year to $851 million. While we admit the imaginable of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.